Incyte Corporation — FY2020 Form 10-K
Business context and reporting period. Incyte is a biopharmaceutical company focused on developing and commercializing therapeutics. This annual filing covers the fiscal year ended December 31, 2020; it also provides unaudited quarterly results. Its principal marketed products included JAKAFI, ICLUSIG, PEMAZYRE and, in U.S. co-commercialization with MorphoSys, MONJUVI. JAKAFI remained the largest revenue source.
Financial performance and liquidity
| Metric | FY2020 | FY2019 | Change / context |
|---|---|---|---|
| Total revenue | $2.667 billion | $2.159 billion | Up 23.5% |
| Product revenue | $2.069 billion | $1.775 billion | Up 16.5%; JAKAFI revenue was $1.938 billion, up 15.0% |
| Product royalties | $393.0 million | $306.3 million | Up 28.3% |
| Milestone and contract revenue | $205.0 million | $77.5 million | Included $170.0 million from Novartis, $30.0 million from Lilly and $5.0 million from Innovent |
| Operating income (loss) | $(263.7) million | $402.0 million | Moved to an operating loss as R&D spending rose substantially |
| Net income (loss) | $(295.7) million | $446.9 million | Basic and diluted EPS were both $(1.36), versus $2.08 basic and $2.05 diluted |
| Operating cash flow | $(124.6) million | $710.7 million | Decrease primarily reflected the MorphoSys upfront payment and working-capital changes |
| Cash, equivalents and marketable securities | $1.801 billion | $2.118 billion | Working capital was $1.729 billion at year-end |
Research and development expense increased to $2.216 billion from $1.154 billion. Key items included $804.5 million of MorphoSys upfront consideration, a $120.0 million priority review voucher and $40.0 million of MacroGenics milestones. Selling, general and administrative expense was $516.9 million, versus $468.7 million. Product costs, including royalties and amortization, were $131.3 million; the implied product gross margin on reported product revenue was approximately 93.7%.
At December 31, 2020, total assets were $3.561 billion and stockholders’ equity was $2.611 billion. No convertible senior notes remained outstanding after conversion of the notes due in 2020. The company reported $61.7 million of lease liabilities and $266.0 million of acquisition-related contingent consideration. Capital expenditures were $187.4 million. Management stated that cash, securities and operating cash flow should meet capital needs for the foreseeable future.
In the fourth quarter of 2020, revenue was $789.5 million and net income was $149.9 million, compared with revenue of $579.4 million and net income of $111.0 million in Q4 2019.
Material changes and developments
- Revenue growth reflected higher product sales and royalties, new PEMAZYRE sales, and increased milestone revenue. JAKAFI product revenue grew by $252.9 million, comprising reported volume growth of $220.4 million and price growth of $32.5 million.
- Profitability reversed to a net loss, principally as R&D expense nearly doubled, including substantial collaboration and development-related charges.
- Liquidity declined: cash, cash equivalents and marketable securities fell by approximately $316.2 million, while operating cash flow shifted from positive to negative.
- FDA approvals expanded the portfolio: PEMAZYRE for a specified cholangiocarcinoma population and MONJUVI with lenalidomide for specified relapsed or refractory DLBCL. Novartis also obtained FDA approval for TABRECTA; Incyte receives royalties and milestones under its collaboration.
Outlook, risks and unusual items
- Outlook: The filing gives no specific numerical revenue, earnings or cash-flow guidance. Development priorities included an NDA submitted for ruxolitinib cream for atopic dermatitis and an sNDA submitted for ruxolitinib in steroid-refractory chronic GVHD. Pemigatinib and tafasitamab were under regulatory review in additional markets.
- COVID-19: Management reported fewer new JAKAFI patient starts and potential clinical-trial and research delays, while stating it had not experienced a material effect to date on commercial results or manufacturing supply. RUXCOVID, testing ruxolitinib in non-mechanically ventilated patients, did not prevent complications versus standard of care. A separate trial in ventilated patients remained ongoing.
- Concentration and competition: Incyte warned that JAKAFI is expected to remain a significant share of revenue. Risks include reimbursement and pricing pressure, specialty-pharmacy and wholesaler concentration, competition, and possible generic entry. A generic applicant had challenged certain JAKAFI patents; the filing provides no assurance that patent protection will prevail.
- Execution and supply: Incyte relies on third parties for manufacturing and has limited or single-source suppliers for some products and materials. Clinical failure, regulatory delays, supply interruption or commercialization challenges could affect results.
- Contingency: A DOJ inquiry and related qui tam complaint concerned speaker and patient-assistance programs. Incyte said it was defending the matter, had filed a motion for summary judgment, and could not estimate the outcome or possible loss; no reserve was recorded.
- Other unusual items: The $266.0 million ICLUSIG-related contingent consideration liability is remeasured using significant unobservable assumptions. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether JAKAFI sales growth and patient starts recover or remain affected by competition, COVID-19 and reimbursement conditions.
- How much of future revenue and earnings depends on milestone payments, royalties and partner performance, and how repeatable 2020’s milestone revenue is.
- Whether major R&D and collaboration expenditures translate into regulatory approvals and sustainable product revenue, including MONJUVI and ruxolitinib cream.
- The status and potential financial impact of the DOJ/qui tam matter and the JAKAFI patent challenge.
- Cash use, capital spending, contingent consideration and lease commitments, including progress on the planned facilities.